Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease.

    Summary
    EudraCT number
    2018-004164-60
    Trial protocol
    NL  
    Global end of trial date
    28 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    05 Jan 2025
    First version publication date
    05 Jan 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CUV040
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT05854784
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    CLINUVEL (UK)
    Sponsor organisation address
    The Old Post Office, 33 Station Road, Egham, Surrey, United Kingdom, TW20 9LA
    Public contact
    Director, Global Clinical Affairs, CLINUVEL (UK) LTD, 0044 1372860765, mail@clinuvel.com
    Scientific contact
    Director, Global Clinical Affairs, CLINUVEL (UK) LTD, 0044 1372860765, mail@clinuvel.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    10 May 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Dec 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Dec 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP).
    Protection of trial subjects
    This study was conducted in accordance with the Declaration of Helsinki, its revisions (Scotland, October 2000 and incorporating Notes of Clarification – Washington, 2002, Tokyo, 2004 and Seoul 2008) and ICH guidelines for Good Clinical Practice (GCP) governing the conduct of studies, and all applicable local regulations. The investigator assured that the study was conducted in accordance with prevailing local laws and regulations. The investigator was responsible for reporting to the Sponsor, the authorities and the Ethics Committee any modifications, safety updates, amendments, and violations of the protocol that impact on subject safety. Prior to any study specific screening procedures, the Investigator had explained to each participant and/or to his/her legal representative, if necessary, the nature of the study, its purpose, procedures to be performed, the necessity for withdrawal of prohibited medication, expected duration, and the benefits and risks of study participation. After this explanation and before any study specific procedures were performed, the subject had voluntarily signed an informed consent statement.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    28 Mar 2023
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Switzerland: 3
    Country: Number of subjects enrolled
    Netherlands: 3
    Worldwide total number of subjects
    6
    EEA total number of subjects
    3
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    5
    From 65 to 84 years
    1
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment was conducted as per the protocol.

    Pre-assignment
    Screening details
    Screening was conducted as per protocol.

    Period 1
    Period 1 title
    Overall Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    SCENESSE® (afamelanotide 16mg)
    Arm description
    Six eligible patients received six doses of afamelanotide 16mg, one dose every 28 days, as a controlled-release formulation.
    Arm type
    Experimental

    Investigational medicinal product name
    SCENESSE® (afamelanotide 16mg)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Implant
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    16mg implant, 1 dose every 28 days, 6 doses in total

    Number of subjects in period 1
    SCENESSE® (afamelanotide 16mg)
    Started
    6
    Completed
    6

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall Period
    Reporting group description
    -

    Reporting group values
    Overall Period Total
    Number of subjects
    6 6
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    5 5
        From 65-84 years
    1 1
    Gender categorical
    Units: Subjects
        Female
    5 5
        Male
    1 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    SCENESSE® (afamelanotide 16mg)
    Reporting group description
    Six eligible patients received six doses of afamelanotide 16mg, one dose every 28 days, as a controlled-release formulation.

    Primary: The change in disease severity in patients with VP as measured by a scoring system (A).

    Close Top of page
    End point title
    The change in disease severity in patients with VP as measured by a scoring system (A). [1]
    End point description
    End point type
    Primary
    End point timeframe
    From baseline to Day 168.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistics are not provided because they are not mandatory for a single arm study.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    2.5 (1.0 to 3.0)
    No statistical analyses for this end point

    Secondary: The change in disease severity in patients with VP as measured by a scoring system (B).

    Close Top of page
    End point title
    The change in disease severity in patients with VP as measured by a scoring system (B).
    End point description
    A lower score indicates a reduced severity of the disease.
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    -3.0 (-5.0 to 0.0)
    No statistical analyses for this end point

    Secondary: The change in disease severity in patients with VP as measured by a scoring system (C).

    Close Top of page
    End point title
    The change in disease severity in patients with VP as measured by a scoring system (C).
    End point description
    A lower score indicates a reduced severity of the disease.
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    -2.0 (-3.0 to 1.0)
    No statistical analyses for this end point

    Secondary: The change in disease severity in patients with VP as measured by a scoring system (D).

    Close Top of page
    End point title
    The change in disease severity in patients with VP as measured by a scoring system (D).
    End point description
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    2.5 (1.0 to 3.0)
    No statistical analyses for this end point

    Secondary: The change in disease severity in patients with VP as measured by a scoring system (E).

    Close Top of page
    End point title
    The change in disease severity in patients with VP as measured by a scoring system (E).
    End point description
    A lower score indicates a reduced severity of the disease.
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    -6.5 (-9.0 to -1.0)
    No statistical analyses for this end point

    Secondary: The change in number of new skin lesions formed.

    Close Top of page
    End point title
    The change in number of new skin lesions formed.
    End point description
    A lower score indicates a reduced severity of the disease.
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Change in number of new skin lesion.
        median (full range (min-max))
    -6.5 (-11.0 to 4.0)
    No statistical analyses for this end point

    Secondary: The change in the Quality of Life in patients with VP as measured by a validated global quality of life tool (A).

    Close Top of page
    End point title
    The change in the Quality of Life in patients with VP as measured by a validated global quality of life tool (A).
    End point description
    Percent activity impairment due to health. A lower score indicates a reduced impairment.
    End point type
    Secondary
    End point timeframe
    Median change from baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    -10.0 (-80.0 to 40.0)
    No statistical analyses for this end point

    Secondary: The change in the Quality of Life in patients with VP as measured by a disease specific tool (B).

    Close Top of page
    End point title
    The change in the Quality of Life in patients with VP as measured by a disease specific tool (B).
    End point description
    A lower score indicates a reduced severity of the disease.
    End point type
    Secondary
    End point timeframe
    From baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
        median (full range (min-max))
    -12.0 (-23.0 to -3.0)
    No statistical analyses for this end point

    Secondary: The change in the Quality of Life in patients with VP as measured by disease specific questionnaire (C).

    Close Top of page
    End point title
    The change in the Quality of Life in patients with VP as measured by disease specific questionnaire (C).
    End point description
    Not appropriate to calculate total scores.
    End point type
    Secondary
    End point timeframe
    From baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Score
    0
    No statistical analyses for this end point

    Secondary: The change in outdoor light exposure over time (Daily Diary).

    Close Top of page
    End point title
    The change in outdoor light exposure over time (Daily Diary).
    End point description
    Median number of daily hours of sunlight exposure.
    End point type
    Secondary
    End point timeframe
    From baseline to Day 168.
    End point values
    SCENESSE® (afamelanotide 16mg)
    Number of subjects analysed
    6
    Units: Change in light exposure over time
        median (full range (min-max))
    0.70 (0.2 to 2.3)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    All adverse events were monitored from baseline until 3 months after end of treatment.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Arm 1
    Reporting group description
    To avoid potential breach of confidentiality and privacy, adverse event information is not released as a rare disease patient may be individually identifiable from a small study.

    Serious adverse events
    Arm 1
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 6 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Arm 1
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 6 (0.00%)
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: To avoid potential breach of confidentiality and privacy, adverse event information is not released as a rare disease patient may be individually identifiable from a small study.

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    N/A
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:19:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA